TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Pharmaust Limited ( (AU:NUZ) ) just unveiled an announcement.
Neurizon Therapeutics Limited has appointed Ms. Justine Conway, Global Head of Business Development at Elanco Animal Health, as a Board Observer. This appointment underscores the strong partnership between Neurizon and Elanco, following a global license agreement for Monepantel, the active ingredient in NUZ-001. The agreement supports Neurizon’s regulatory foundations and provides access to critical data for future clinical trials and potential global market entry. Ms. Conway’s extensive experience in healthcare and strategic partnerships is expected to enhance Neurizon’s governance and aid in advancing NUZ-001 towards late-stage development and global commercialization.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company is advancing its lead drug candidate, NUZ-001, for the treatment of ALS, the most common form of motor neuron disease. Neurizon aims to accelerate access to effective ALS treatments and explore broader neurodegenerative applications through international collaborations and rigorous clinical programs.
Average Trading Volume: 778,681
Technical Sentiment Signal: Sell
Current Market Cap: A$58.82M
For detailed information about NUZ stock, go to TipRanks’ Stock Analysis page.